Hailing the government's move, Surajit Pal, pharma analyst at Prabhudas Lilladher, says the aim of regulation is to prevent rampant use of antibiotics. He says Abbott is likely to be severely impacted by the move as it has around 15.4 percent exposure to fixed-dosed combinations.
first published: Mar 14, 2016 09:18 am
A collection of the most-viewed Moneycontrol videos.

LIVE: Moneycontrol Mutual Fund Summit 2025 |Bengaluru| Decoding Purpose, Products, Tech

Nifty, Sensex Gain On Easing US–China Trade Tensions, Fed Rate Cut Hopes | Closing Bell

Live: Nifty enters busy Q2 earnings week, FOMC meeting | Opening Bell

The Tenant Diwali Special: From Mumbai Slums to Alibaug Villas: 2025 Recap
You are already a Moneycontrol Pro user.

